Sino Biopharmaceutical Ltd 2019 SR
The report highlights Sino Biopharmaceutical's 2019 ESG performance, focusing on R&D innovation and environmental management. The company invested RMB 2.399 billion in R&D, with 28 products obtaining drug registration approval. Key environmental achievements include the certification of major subsidiaries under ISO 14001 and ISO 50001 standards. The group also emphasized employee development, maintaining a workforce of 23,475 and achieving zero work-related fatalities. Social contributions included significant donations for disaster relief and the establishment of liver disease research funds.
Company: Sino Biopharmaceutical Ltd
Sector: Manufacturing
Country: Hong Kong
Year: 2019
Type: SR
Pages: 37
Back to company
Sino Biopharmaceutical Ltd
ESG Report
The report highlights Sino Biopharmaceutical's 2019 ESG performance, focusing on R&D innovation and environmental management. The company invested RMB 2.399 billion in R&D, with 28 products obtaining drug registration approval. Key environmental achievements include the certification of major subsidiaries under ISO 14001 and ISO 50001 standards. The group also emphasized employee development, maintaining a workforce of 23,475 and achieving zero work-related fatalities. Social contributions included significant donations for disaster relief and the establishment of liver disease research funds.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Workplace Fatalities
Employees